Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- UT MD Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- UT MD Anderson - League City — League City, Texas
- MD Anderson in Sugar Land — Sugar Land, Texas
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Mays Cancer Center — San Antonio, Texas
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas Houston Health Science Center — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of f…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03741673
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Baylor Scott & White Medical Center — Temple, Texas
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Community Clinical Trials — Kingwood, Texas
- Tranquil Clinical Research — Webster, Texas
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Texas: - UT Southwestern — Dallas, Texas
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Texas: - Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
- UT Health San Antonio Mays Cancer Center — San Antonio, Texas
Phase 2 Recruiting Academic/Other
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein,…
Sponsor: The University of Texas Health Science Center at San Antonio
NCT ID: NCT04559230
Sites in Texas: - Texas Oncology Austin — Austin, Texas
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Academic/Other
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety…
Sponsor: Washington University School of Medicine
NCT ID: NCT06639607
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant gliom…
Sponsor: Plus Therapeutics
NCT ID: NCT01906385
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- The Cancer Therapy and Research Center at UTHSCSA — San Antonio, Texas
Phase 1, Phase 2 Recruiting Academic/Other
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical r…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06672575
Sites in Texas: - The University of Texas M. D. Anderson Cancer Center — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy. To lea…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06649058
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT05048212
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT05700721
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas